Korean Circ J.  2007 Oct;37(10):464-469. 10.4070/kcj.2007.37.10.464.

The Role of Brain Natriuretic Peptide in the Patients with Acute Dyspnea in the Emergency Department

• Choi JY

• KMID: 2227046
• DOI: http://doi.org/10.4070/kcj.2007.37.10.464

Abstract

For the acutely ill patients who present to the emergency department (ED) with dyspnea, an incorrect or delayed diagnosis of congestive heart failure (CHF) could place the patient at an increased risk for both morbidity and mortality. Therefore, a rapid and accurate diagnosis of CHF is mandatory for administering appropriate and efficacious management. Unfortunately, the signs and symptoms, and readily available emergency diagnostics are neither sensitive nor specific enough for diagnosing CHF alone. Brain natriuretic peptide (BNP) is secreted by myocytes in response to ventricular stretch and it has long been thought that BNP could become a biochemical marker for CHF and could be a useful tool in the diagnosis and exclusion of CHF if it is applied appropriately.

Keyword

Dyspnea; Heart failure, congestive; B-type natriuretic peptide

MeSH Terms

Biomarkers
Brain*
Delayed Diagnosis
Diagnosis
Dyspnea*
Emergencies*
Emergency Service, Hospital*
Heart Failure
Humans
Mortality
Muscle Cells
Natriuretic Peptide, Brain*
Natriuretic Peptide, Brain

Reference

1. Han SW, Ryu KH, Chae SC, et al. Multicenter analysis of clinical characteristics and prognostic factors of patients with congestive heart failure in Korea. Korean Circ J. 2005. 35:357–361.

2. Struthers AD. The diagnosis of heart failure. Heart. 2000. 84:334–338.

3. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: which features are any use? QJM. 1997. 90:335–339.

4. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001. 37:379–385.

5. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996. 312:222.

6. Kisch B. Electron microscopy of the atrium of the heart: I. Guinea pig. Exp Med Surg. 1956. 14:99–112.

7. Kangawa K, Fukuda A, Minamino N, Matsuo H. Purification and complete amino sequence of beta-rat atrial natriuretic polypeptide (beta-rANP) at 5000 daltons. Biochem Biophys Res Commun. 1984. 119:933–940.

8. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988. 332:78–81.

9. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995. 96:1280–1287.

10. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail. 2004. 6:257–260.

11. Kelly R, Struthers AD. Are natriuretic peptides clinically useful as markers of heart failure? Ann Clin Biochem. 2001. 38:94–102.

12. Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol. 1996. 77:828–831.

13. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004. 350:655–663.

14. Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 2002. 144:834–839.

15. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004. 164:1978–1984.

16. Choi SH, Park DY, Lee SW, Hong YS, Kim SJ, Lee JK. Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnea visiting emergency departments: a study on Korean patients visiting emergency departments. Emerg Med J. 2007. 24:343–347.

17. Kwon SH, On YK, Han DH, et al. Usefulness of B-type natriuretic peptide in congestive heart failure. Korean Circ J. 2003. 33:695–700.

18. Kang DH, Kim MJ, Kang SJ, et al. Role of B-type natriuretic peptide in diagnosis and follow-up of diastolic heart failure. Korean Circ J. 2006. 36:359–365.

19. Kim SH, Kim JS, Baek KK, et al. Role of NT-proPNP in evaluation of functional status in congestive heart failure. Korean Circ J. 2004. 34:894–899.

20. Song BG, Jeon ES, Kim YH, et al. Correlation between levels of n-terminal pro-B-type natriuretic peptide and degrees of heart failure. Korean J Med. 2004. 66:33–40.

21. Chung IH, Yoo BS, Ryu HY, et al. The relationship between the early follow-u BNP level and congestive status or prognosis in acute heart failure. Korean Circ J. 2006. 36:200–207.

22. Yoo BS, Kim WJ, Jung HS, et al. The clinical experiences of B-type natriuretic peptide blood concentrations for diagnosis in congestive heart failure. Korean Circ J. 2004. 34:684–692.

23. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002. 39:202–209.

24. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002. 347:161–167.

25. Maisel AS, McCord J, Nowak RM, et al. Bedside B-tyue natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. J Am Coll Cardiol. 2003. 41:2010–2017.

26. Knudsen CW, Clopton P, Westheim A, et al. Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. Ann Emerg Med. 2005. 45:573–580.

27. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation. 2002. 106:416–422.

28. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med. 2003. 4:Suppl 4. S13–S19.

29. Bonow R, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Ann Intern Med. 1992. 117:502–510.

30. Thomas JT, Kelly RF, Thomas SJ, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med. 2002. 112:437–445.

31. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide (BNP) in diagnosing diastolic dysfunction. Circulation. 2002. 105:595–601.

32. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001. 141:367–374.

33. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997. 96:509–516.

34. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001. 38:1934–1941.

35. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and orbidity in the Valsartan Heart Failure trial (Val-HeFT). Circulation. 2003. 107:1278–1283.

36. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001. 37:386–391.

37. Kuster GM, Tanner H, Printzen G, Suter TM, Mohacsi P, Hess OM. B-type natriuretic peptide for diagnosis and treatment of congestive heart failure. Swiss Med Wkly. 2002. 132:623–628.

38. Bettencourt P, Frioes F, Azevedo A, et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol. 2004. 93:45–48.

39. Maisel A, Hollander JE, Guss D, et al. Primary results of the rapid emergency department heart failure outpatient trial (REDHOT). J Am Coll Cardiol. 2004. 44:1328–1333.

40. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002. 39:131–138.

41. Januzzi JI, Sakhuja R, O'Donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006. 166:315–320.

42. Shin MS, Ahn TH, Choi IS, Shin EK. Changes in plasma level of B-type natriuretic peptide and myocardial performance index according to clinical improvement in patients with heart failure. Korean J Med. 2003. 65:535–542.

43. Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 2001. 76:1111–1119.

44. Jun SH, Choi SJ, Kim JK, Hwang SD. Clinical benefits of serum BNP measurement in patients with chronic kidney disease. Korean J Med. 2005. 69:135–143.

45. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003. 41:571–579.

46. Wang HS, Yoo BS, Chung IH, et al. Is B-type natriuretic peptide (BNP) measurement useful test for diagnosing systolic heart failure in patients with moderate to severe renal insufficiency? Korean Circ J. 2005. 35:897–903.

47. Naganuma T, Sugimura K, Wada S, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 2002. 22:437–444.

48. Logeart D, Saudubray C, Beyne P, et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol. 2002. 40:1794–1800.

49. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002. 40:976–982.

50. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med. 2004. 164:2247–2252.

51. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004. 350:647–654.